Effect of Fenoldopam Mesylate in Critically Ill Patients at Risk for Acute Renal Failure is Dose Dependent

References

• Liano F.; Pascual J. Outcomes in acute renal failure. Semin. Nephrol. 1998, 18 (5), 541–550. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Levy E M.; Viscoli C M.; Horwitz R I. The effect of acute renal failure on mortality. A cohort analysis. JAMA 1996, 275 (19), 1489–1494. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Groeneveld A B.; Tran D D.; van der Meulen J.; Nauta J J.; Thijs L G. Acute renal failure in the medical intensive care unit: predisposing, complicating factors and outcome. Nephron 1991, 59 (4), 602–610. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Lee M R. Dopamine and the kidney: ten years on. Clin. Sci. (London) 1993, 84 (4), 357–375.
   PubMedGoogle Scholar
• Bellomo R.; Chapman M.; Finfer S.; Hickling K.; Myburgh J. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand intensive care society (ANZICS) clinical trials group. Lancet 2000, 356 (9248), 2139–2143. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Chertow G M.; Sayegh M H.; Allgren R L.; Lazarus J M. Is the administration of dopamine associated with adverse or favorable outcomes in acute renal failure? Auriculin anaritide acute renal failure study group. Am. J. Med. 1996, 101 (1), 49–53. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Thompson B T.; Cockrill B A. Renal-dose dopamine: a siren song?. Lancet 1994, 344 (8914), 7–8. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Segal J M.; Phang P T.; Walley K R. Low-dose dopamine hastens onset of gut ischemia in a porcine model of hemorrhagic shock. J. Appl. Physiol. 1992, 73 (3), 1159–1164. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Devins S S.; Miller A.; Herndon B L.; O'Toole L.; Reisz G. Effects of dopamine on T-lymphocyteproliferative responses and serum prolactin concentrations in critically ill patients. Crit. Care Med. 1992, 20 (12), 1644–1649. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Watkins H.; DeFeo M L.; Diewati A.; Lokhandwala M F. Effects of DA-1 receptor stimulation with fenoldopam on renal sodium excretion, plasma renin activity, plasma aldosterone and atrial natriuretic factor in anesthetized dogs. FASEB J. 1988, 2, A605.
   Google Scholar
• Allison N L.; Dubb J W.; Ziemniak J A.; Alexander F.; Stote R M. The effect of fenoldopam, a dopaminergic agonist, on renal hemodynamics. Clin. Pharmacol. Ther. 1987, 41 (3), 282–288. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Tumlin J A.; Wang A.; Murray P T.; Mathur V S. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy. Am. Heart J. 2002, 143 (5), 894–903. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Garwood S.; Swamidoss C P.; Davis E A.; Samson L.; Hines R L. A case series of low-dose fenoldopam in seventy cardiac surgical patients at increased risk of renal dysfunction. J. Cardiothorac. Vasc. Anesth. 2003, 17 (1), 17–21. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Stone G W.; McCullough P A.; Tumlin J A.; Lepor N E.; Madyoon H.; Murray P.; Wang A.; Chu A A.; Schaer G L.; Stevens M.; Wilensky R L.; O'Neill W W. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 2003, 290 (17), 2284–2291. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hunter D W.; Chamsuddin A.; Bjarnason H.; Kowalik K. Preventing contrast-induced nephropathy with fenoldopam. Tech. Vasc. Interv. Radiol. 2001, 4 (1), 53–56. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Mathur V S.; Swan S K.; Lambrecht L J.; Anjum S.; Fellmann J.; McGuire D.; Epstein M.; Luther R R. The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects. Crit. Care Med. 1999, 27 (9), 1832–1837. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit. Care Med. 1992, 20 (6), 864–874.
   PubMed Web of Science ®Google Scholar
• Hamel M B.; Phillips R S.; Davis R B.; Desbiens N.; Connors A F., Jr.; Teno J M.; Wenger N.; Lynn J.; Wu A W.; Fulkerson W.; Tsevat J. Outcomes and cost-effectiveness of initiating dialysis and continuing aggressive care in seriously ill hospitalized adults. SUPPORT investigators. Study to understand prognoses and preferences for outcomes and risks of treatments. Ann. Intern. Med. 1997, 127 (3), 195–202. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Lameire N.; Vanholder R. Pathophysiologic features and prevention of human and experimental acute tubular necrosis. J. Am. Soc. Nephrol. 2001, 12 (Suppl. 17), S20–32. [PUBMED], [INFOTRIEVE]
   Google Scholar
• Allgren R L.; Marbury T C.; Rahman S N.; Weisberg L S.; Fenves A Z.; Lafayette R A.; Sweet R M.; Genter F C.; Kurnik B R.; Conger J D.; Sayegh M H. Anaritide in acute tubular necrosis. Auriculin anaritide acute renal failure study group. N. Engl. J. Med. 1997, 336 (12), 828–834. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Lewis J.; Salem M M.; Chertow G M.; Weisberg L S.; McGrew F.; Marbury T C.; Allgren R L. Atrial natriuretic factor in oliguric acute renal failure. Anaritide acute renal failure study group. Am. J. Kidney Dis. 2000, 36 (4), 767–774. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Miller S B.; Martin D R.; Kissane J.; Hammerman M R. Insulin-like growth factor I accelerates recovery from ischemic acute tubular necrosis in the rat. Proc. Natl. Acad. Sci. U. S. A. 1992, 89 (24), 11876–11880. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Hirschberg R.; Kopple J.; Lipsett P.; Benjamin E.; Minei J.; Albertson T.; Munger M.; Metzler M.; Zaloga G.; Murray M.; Lowry S.; Conger J.; McKeown W.; O'shea M.; Baughman R.; Wood K.; Haupt M.; Kaiser R.; Simms H.; Warnock D.; Summer W.; Hintz R.; Myers B.; Haenftling K.; Capra W. Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. Kidney Int. 1999, 55 (6), 2423–2432. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gilbert T B.; Hasnain J U.; Flinn W R.; Lilly M P.; Benjamin M E. Fenoldopam infusion associated with preserving renal function after aortic cross-clamping for aneurysm repair. J. Cardiovasc. Pharmacol. Ther. 2001, 6 (1), 31–36. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Halpenny M.; Lakshmi S.; O'Donnell A.; O'Callaghan-Enright S.; Shorten G D. Fenoldopam: renal and splanchnic effects in patients undergoing coronary artery bypass grafting. Anaesthesia 2001, 56 (10), 953–960. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• de Mendonca A.; Vincent J L.; Suter P M.; Moreno R.; Dearden N M.; Antonelli M.; Takala J.; Sprung C.; Cantraine F. Acute renal failure in the ICU: risk factors and outcome evaluated by the SOFA score. Intensive Care Med. 2000, 26 (7), 915–921. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Wilkins R G.; Faragher E B. Acute renal failure in an intensive care unit: incidence, prediction and outcome. Anaesthesia 1983, 38 (7), 628–634. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar